Acceptance of preventive treatment in migraine patients: Results of a survey

被引:5
|
作者
Smelt, Antonia F. H. [1 ]
Eijsenga, Simon J. [1 ]
Assendelft, Willem J. J. [1 ]
Blom, Jeanet W. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, NL-2300 RC Leiden, Netherlands
关键词
migraine; preventive treatment; profylaxis; general practice; acceptance; PREVALENCE; HEADACHE; MEDICATION; THERAPY; BURDEN; IMPACT;
D O I
10.3109/13814788.2012.708332
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The number of migraine patients eligible for preventive treatment is considerably higher than the number of patients actually using it. This study explores reasons for this discrepancy. Methods: An explorative survey among patients and their general practitioners (GPs) participating in a trial on preventive medication. Migraine patients who were eligible for preventive treatment (n = 75) attended an evaluation consultation with their GP to optimize migraine treatment. GPs and patients who did not start preventive treatment were asked if they had discussed the possibility of preventive treatment and, if so, why they decided not to start it. Results: Of the 32 GPs, 8 (25%) did not discuss the possibility of preventive treatment with their patients; in 4 because of perceived lack of effectiveness. Patients who did not start preventive treatment (n = 43) used less triptans and had less psychological distress compared to those who did start (n = 32). Main reasons for patients not starting were negative attitudes towards medication in general, fear of medication side-effects, previous unsuccessful attempts, attacks not being severe enough, and impact of migraine on daily life acceptable. Conclusion: The decision of the individual patient and their GP to start preventive treatment is not only determined by attack frequency, but also depends on the impact of the headache attacks on their daily life and their negative attitude towards medication.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] Preventive treatment in migraine. Used drugs and related variables. Results of the European work and migraine survey
    Teofila Vicente-Herrero, Ma
    Ramirez-Iniguez de la Torre, Ma. Victoria
    Ruiz-de la Torre, Elena
    Reinoso-Barbero, Luis
    REVISTA MEXICANA DE NEUROCIENCIA, 2020, 21 (03): : 82 - 89
  • [2] Preventive Treatment for Patients With Migraine and Cardiovascular Disease
    Panesar, Kiran
    US PHARMACIST, 2018, 43 (12) : 38 - 44
  • [3] The patients' attitude towards treatment of migraine - results from a large European survey in migraine sufferers
    Turner, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 199 - 199
  • [4] Migraine: preventive treatment
    Silberstein, SD
    Goadsby, PJ
    CEPHALALGIA, 2002, 22 (07) : 491 - 512
  • [5] Preventive treatment of migraine
    Silberstein, Stephen D.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (08) : 410 - 415
  • [6] Preventive Treatment of Migraine
    Shapiro, Robert E.
    HEADACHE, 2012, 52 : 65 - 69
  • [7] Preventive Migraine Treatment
    Silberstein, Stephen D.
    NEUROLOGIC CLINICS, 2009, 27 (02) : 429 - +
  • [8] Preventive treatment of migraine
    Silberstein, SD
    Freitag, FG
    NEUROLOGY, 2003, 60 (07) : S38 - S44
  • [9] The preventive treatment of migraine
    Bigal, Marcelo E.
    Lipton, Richard B.
    NEUROLOGIST, 2006, 12 (04) : 204 - 213
  • [10] Preventive Treatment of Migraine
    Todd, Candice M.
    Sandoe, Claire H.
    Lay, Christine
    SEMINARS IN NEUROLOGY, 2022, 42 (04) : 503 - 511